早期运动并发症帕金森病患者丘脑底核刺激联合药物治疗与单纯药物治疗的行为学结局(EARLYSTIM试验):一项开放标签随机试验的二次分析
EARLYSTIM试验二次分析纳入251例早期运动并发症帕金森病患者,随机分配至丘脑底核刺激联合药物组(124例)或单纯药物组(127例),随访2年。联合治疗组神经精神波动和高多巴胺能行为障碍较单纯药物组改善,两组低多巴胺能行为、淡漠和抑郁无差异。
要点
- 丘脑底核刺激联合药物组神经精神波动平均变化-0.65分,单纯药物组-0.02分,组间差异显著(p=0.0028)。
- 高多巴胺能行为障碍亚评分联合组-1.26分,单纯药物组+1.12分,组间差异显著(p<0.0001)。
- 低多巴胺能行为障碍、淡漠和抑郁评分两组间无显著差异。
核心结论
- 在伴早期运动并发症的帕金森病患者中,丘脑底核刺激联合药物治疗较单纯药物治疗整体行为学结局更好。
- 若因致残性运动并发症考虑手术,高多巴胺能行为和神经精神波动的存在可作为支持丘脑底核刺激的额外理由。
研究设计与样本
- 平行、开放标签研究(EARLYSTIM),在法国8个和德国9个手术中心开展。
- 纳入因早期运动并发症致残的帕金森病患者,按1:1随机分配至单纯药物治疗组(127例)或双侧丘脑底核刺激联合药物治疗组(124例),共251例。
- 主要结局为基线至2年生活质量平均变化;本报告为二次分析,评估行为学结局。
主要发现
- 2年随访时,双侧丘脑底核刺激联合药物组左旋多巴等效剂量减少39%(-363.3 mg/天[SE 41.8]),单纯药物组增加21%(245.8 mg/天[SE 40.4])(p<0.0001)。
- 神经精神波动在联合组下降(平均变化-0.65分[SE 0.15]),单纯药物组无变化(-0.02分[SE 0.15]),组间变化差异显著(p=0.0028)。
- 2年时,Ardouin量表高多巴胺能行为障碍亚评分联合组下降(平均变化-1.26分[SE 0.35]),单纯药物组升高(1.12分[SE 0.35]),组间差异显著(p<0.0001)。
- Ardouin量表低多巴胺能行为障碍亚评分、Starkstein淡漠量表评分和Beck抑郁量表评分的2年平均变化两组间无差异。
- 联合组12例停用抗抑郁药 vs 单纯药物组4例;单纯药物组9例开始使用抗精神病药 vs 联合组1例;2年随访期间联合组2例、单纯药物组1例自杀死亡。
关键数值与推荐
- 行为评估采用Ardouin行为量表(Ardouin Scale of Behavior in Parkinson's Disease),淡漠采用Starkstein淡漠量表,抑郁采用Beck抑郁量表。
- 统计分析采用广义估计方程(GEE)回归模型分析单个条目,混合模型回归分析Ardouin量表亚评分及淡漠和抑郁量表。
临床怎么用
- 作者认为,在因致残性运动并发症考虑手术时,高多巴胺能行为和神经精神波动的存在可作为支持丘脑底核刺激的额外理由。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although subthalamic stimulation is a recognised treatment for motor complications in Parkinson's disease, reports on behavioural outcomes are controversial, which represents a major challenge when counselling candidates for subthalamic stimulation. We aimed to assess changes in behaviour in patients with Parkinson's disease receiving combined treatment with subthalamic stimulation and medical therapy over a 2-year follow-up period as compared with the behavioural evolution under medical therapy alone. METHODS: We did a parallel, open-label study (EARLYSTIM) at 17 surgical centres in France (n=8) and Germany (n=9). We recruited patients with Parkinson's disease who were disabled by early motor complications. Participants were randomly allocated (1:1) to either medical therapy alone or bilateral subthalamic stimulation plus medical therapy. The primary outcome was mean change in quality of life from baseline to 2 years. A secondary analysis was also done to assess behavioural outcomes. We used the Ardouin Scale of Behavior in Parkinson's Disease to assess changes in behaviour between baseline and 2-year follow-up. Apathy was also measured using the Starkstein Apathy Scale, and depression was assessed with the Beck Depression Inventory. The secondary analysis was done in all patients recruited. We used a generalised estimating equations (GEE) regression model for individual items and mixed model regression for subscores of the Ardouin scale and the apathy and depression scales. This trial is registered with ClinicalTrials.gov, number NCT00354133. The primary analysis has been reported elsewhere; this report presents the secondary analysis only. FINDINGS: Between July, 2006, and November, 2009, 251 participants were recruited, of whom 127 were allocated medical therapy alone and 124 were assigned bilateral subthalamic stimulation plus medical therapy. At 2-year follow-up, the levodopa-equivalent dose was reduced by 39% (-363·3 mg/day [SE 41·8]) in individuals allocated bilateral subthalamic stimulation plus medical therapy and was increased by 21% (245·8 mg/day [40·4]) in those assigned medical therapy alone (p<0·0001). Neuropsychiatric fluctuations decreased with bilateral subthalamic stimulation plus medical therapy during 2-year follow-up (mean change -0·65 points [SE 0·15]) and did not change with medical therapy alone (-0·02 points [0·15]); the between-group difference in change from baseline was significant (p=0·0028). At 2 years, the Ardouin scale subscore for hyperdopaminergic behavioural disorders had decreased with bilateral subthalamic stimulation plus medical therapy (mean change -1·26 points [SE 0·35]) and had increased with medical therapy alone (1·12 points [0·35]); the between-group difference was significant (p<0·0001). Mean change from baseline at 2 years in the Ardouin scale subscore for hypodopaminergic behavioural disorders, the Starkstein Apathy Scale score, and the Beck Depression Inventory score did not differ between treatment groups. Antidepressants were stopped in 12 patients assigned bilateral subthalamic stimulation plus medical therapy versus four patients allocated medical therapy alone. Neuroleptics were started in nine patients assigned medical therapy alone versus one patient allocated bilateral subthalamic stimulation plus medical therapy. During the 2-year follow-up, two individuals assigned bilateral subthalamic stimulation plus medical therapy and one patient allocated medical therapy alone died by suicide. INTERPRETATION: In a large cohort with Parkinson's disease and early motor complications, better overall behavioural outcomes were noted with bilateral subthalamic stimulation plus medical therapy compared with medical therapy alone. The presence of hyperdopaminergic behaviours and neuropsychiatric fluctuations can be judged additional arguments in favour of subthalamic stimulation if surgery is considered for disabling motor complications. FUNDING: German Federal Ministry of Education and Research, French Programme Hospitalier de Recherche Clinique National, and Medtronic.
引用
- Lhommée E, Wojtecki L, Czernecki V, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018. PMID: 29452685. doi:10.1016/S1474-4422(18)30035-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。